Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
Saved in:
| Title: | Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. |
|---|---|
| Authors: | Horwitz SM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Feldman TA; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA., Ye JC; University of Michigan, Ann Arbor, MI, USA., Khodadoust MS; Stanford University School of Medicine, Palo Alto, CA, USA., Munoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Hamlin PA; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kim YH; Stanford University School of Medicine, Palo Alto, CA, USA., Wilcox RA; University of Michigan, Ann Arbor, MI, USA., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Coffey G; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Innes A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Betz A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Holland J; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Guzman CB; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Smith SM; University of Chicago Medicine, Chicago, IL, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2025 Jun; Vol. 66 (6), pp. 1100-1110. Date of Electronic Publication: 2025 Feb 08. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
